Biogen & Merck Sign $130 Million Deal
US drug companies Biogen and Merck & Co have signed a collaborativeagreement for the development of an aerosolized anti-VLA-4 small molecule drug as a treatment for asthma and oral VLA-4 inhibitors.
Under the terms of the agreement, Merck is to pay a $15 million upfront fee, with further milestone payments that could total approximately $130 million. Biogen will pay $21 million to Merck if all milestones are met. The companies will share what they describe as an "escalating double-digit royalty schedule."
In addition, Merck's Japanese affiliate, Banyu Pharmaceutical Co, will manage clinical development and approvals in Japan of one of Biogen's proprietary compounds. Biogen will retain the marketing rights to the compound, which has not yet been selected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze